Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Mercedes AMG PETRONAS Formula One Team | UNKNOWN |
| Imperial College London | OTHER |
Not provided
Not provided
Not provided
This study is a safety assessment of the iZephyr hood a novel aerosol removal device in patients receiving non invasive ventilation for COVID-19.
Demonstrate that safety and suitability of the iZephyr Hood in patients receiving non-invasive ventilation (NIV) or high flow oxygen therapy (HFOT).
Determine the user acceptability of the iZephyr Hood in patients receiving NIV and HFOT.
Determine the reduction in aerosol spread of COVID-19 viral particles when using the Zephyr hood in patients using non-invasive ventilation or high flow oxygen.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| With i-zephyr | Experimental | using the hood |
|
| Without i-zephyr | No Intervention | Not using the hood |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| iZephyr hood | Device | Assessment of an aerosol containment device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Determine the background concentration of SARS-Co-V2 around COVID patients receiving NIV | Air and surface sampling for SARS Co-V2 around COVID patients receiving non invasive ventilation or high flow oxygen therapy. | 3 month |
| Determine the background concentration of SARS-Co-V2 when the iZephyr hood is in use | Air and surface sampling for SARS Co-V2 around COVID patients receiving non invasive ventilation or high flow oxygen therapy inside an iZephyr hood. | 12 months |
| Impact of iZephyr hood on environmental SARS Co-V2 contamination | Determine if there is a change in the concentration of SARS-Co-V2 virus on the surfaces and in the air samples surrounding a COVID-19 positive patient whilst using the iZephyr compared to when not using the iZephyr. | 12 months |
Not provided
Not provided
Inclusion Criteria:
Adult COVID-19 negative patients who are requiring non-invasive ventilation (phase II)
Adult COVID-19 positive patients who are requiring non-invasive ventilation (Phase III)
Exclusion Criteria:
Patients under the age of 18 years or those lacking capacity
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Priscilla Humado | Contact | 02033137306 | priscilla.humado1@nhs.net |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Environmental contamination of SARS Co-V2 (air and surface) will be tested around COVID patients receiving Non-invasive ventilation or high flow oxygen therapy before using the iZephyr hood and then with the iZephyr hood in place, to determine if the hood changes the amount of environmental contamination
Not provided
Not provided
Not provided
Not provided
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |